Back to Search Start Over

Venom peptides in cancer therapy: An updated review on cellular and molecular aspects.

Authors :
Mirzaei S
Fekri HS
Hashemi F
Hushmandi K
Mohammadinejad R
Ashrafizadeh M
Zarrabi A
Garg M
Source :
Pharmacological research [Pharmacol Res] 2021 Feb; Vol. 164, pp. 105327. Date of Electronic Publication: 2020 Dec 01.
Publication Year :
2021

Abstract

Based on the high incidence and mortality rates of cancer, its therapy remains one of the most vital challenges in the field of medicine. Consequently, enhancing the efficacy of currently applied treatments and finding novel strategies are of great importance for cancer treatment. Venoms are important sources of a variety of bioactive compounds including salts, small molecules, macromolecules, proteins, and peptides that are defined as toxins. They can exhibit different pharmacological effects, and in recent years, their anti-tumor activities have gained significant attention. Several different compounds are responsible for the anti-tumor activity of venoms, and peptides are one of them. In the present review, we discuss the possible anti-tumor activities of venom peptides by highlighting molecular pathways and mechanisms through which these molecules can act effectively. Venom peptides can induce cell death in cancer cells and can substantially enhance the efficacy of chemotherapy and radiotherapy. Also, the venom peptides can mitigate the migration of cancer cells via suppression of angiogenesis and epithelial-to-mesenchymal transition. Notably, nanoparticles have been applied in enhancing the bioavailability of venom peptides and providing targeted delivery, thereby leading to their elevated anti-tumor activity and potential application for cancer therapy.<br /> (Copyright © 2020 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1096-1186
Volume :
164
Database :
MEDLINE
Journal :
Pharmacological research
Publication Type :
Academic Journal
Accession number :
33276098
Full Text :
https://doi.org/10.1016/j.phrs.2020.105327